What Циклосерин Treats: Main Uses and Benefits

The primary therapeutic use of Cycloserine is associated with conditions involving complex bacterial infections. The medicine is commonly used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed.

---

Key Therapeutic Contexts

Cycloserine is applied in addressing active pulmonary and extra-pulmonary tuberculosis infections that have become resistant to standard treatments (MDR-TB and XDR-TB). This use is relevant in contexts involving heightened systemic burden and supports patients during difficult episodes.

The medication plays a role in managing the symptoms related to systemic imbalance that characterize chronic TB, such as persistent fever, night sweats, and unexplained weight loss. Additionally, in a secondary, specialized capacity, it may be part of symptomatic management to address acute UTIs caused by specific, susceptible bacterial strains in situations where patients experience persistent symptoms.

“The medication is considered relevant for conditions where symptoms may intensify temporarily, contributing to easing the overall symptom load.”

Quick Fact: Relief for Resistant Infections
Cycloserine is used for managing symptoms associated with conditions marked by increased physiological stress, and supports patients by contributing to easing the overall symptom load during the symptomatic periods.

Eligibility for Cycloserine (Циклосерин)

Official regulatory information identifies specific patient populations who must not use this medicine due to a high risk of severe adverse effects, primarily involving the central nervous system (CNS).

Contraindicated Populations (Must Not Use)	Special Restriction / Use Not Established
Hypersensitivity to cycloserine or its components.	Severe Renal Insufficiency/Failure (Contraindicated).
Epilepsy or a history of convulsive/seizure disorders.	Alcohol Use: Excessive concurrent use is Contraindicated.
History of Mental Depression, Severe Anxiety, or Psychosis.	Pediatric Use: Safety and effectiveness have not been established.
Excessive Concurrent Use of Alcohol (Contraindicated).	Pregnancy: Use only if clearly needed and when no suitable alternatives exist.

Cycloserine is substantially excreted by the kidney, and its use is strictly limited or prohibited in cases of severe renal impairment to prevent the buildup of toxic drug levels in the blood. Patients with any history of the listed psychiatric or seizure disorders are at a significantly increased risk for neurotoxicity. Due to potential risks, caution and careful monitoring are required when used during pregnancy, and a decision on discontinuing nursing or the drug must be made during lactation.

Interactions with other medicines and products

The interaction profile for Cycloserine is defined by documented risks of pharmacodynamic neurotoxicity reinforcement and pharmacokinetic exposure modification, as detailed in official government prescribing information.

Interacting Substance	Interaction Classification	Official Regulatory Outcome
Alcohol (Ethanol)	Contraindicated Combination	Prohibited due to potentiation of neurotoxicity and increased possibility of epileptic episodes (seizures).
Isoniazid	Clinically Significant	Increases Cycloserine toxicity by decreasing its metabolism, leading to excessive blood levels and enhanced CNS effects.
Ethionamide	Clinically Significant	Potentiates neurotoxic side effects; co-administration may result in enhanced CNS toxicity.
Phenytoin	Clinically Significant	Cycloserine inhibits the hepatic metabolism of Phenytoin, resulting in elevated Phenytoin concentration.
High-fat Meal	Administration Constraint	Negatively affects the absorption of Cycloserine and is advised to be avoided.

The documented drug-drug interactions, such as those with Isoniazid and Ethionamide, primarily concern additive risks of central nervous system toxicity. Furthermore, Cycloserine is documented to interact with other medications by inhibiting metabolic pathways, such as its effect on the hepatic metabolism of Phenytoin. An administration constraint also exists regarding food, as a high-fat meal negatively affects drug absorption. Additionally, the regulatory profile notes that in patients with reduced renal function, inadequate clearance is an important condition that causes excessive blood levels, increasing the potential for toxicity.

D-Cycloserine's mechanism involves structurally mimicking the natural amino acid D-alanine, which allows it to interfere directly with the essential enzymatic processes required for bacterial cell wall formation. The drug acts as a competitive inhibitor against two critical cytosolic enzymes: Alanine Racemase and D-Alanine:D-Alanine Ligase. By binding to the active sites of these targets, Cycloserine prevents the formation of the D-Ala-D-Ala dipeptide, an essential molecular precursor. This interference interrupts the initial steps of the peptidoglycan biosynthesis pathway, which provides the foundation for bacterial structural support.

The primary physiological consequence of this inhibition is the failure of the susceptible bacterium to construct a stable and rigid cell wall. Without the complete peptidoglycan layer, the bacterial structure cannot withstand internal osmotic pressure, leading to cell leakage and eventual lysis (cell breakdown) or the complete cessation of growth. This cellular-level failure to maintain viability is the foundation of the drug's action against susceptible mycobacteria.

The drug's mechanism of action is functionally constrained by factors such as its bacterial transport and the concentration of its target enzymes. Overexpression of Alanine Racemase or D-Alanine:D-Alanine Ligase can functionally override the competitive block.

Cycloserine is administered exclusively by the oral route, typically supplied in 250 mg hard capsules. The use of this medicine is defined as a component of a multi-drug regimen; it is not used as a standalone treatment against infection.

For adult patients, the standard daily dose ranges from 500 mg to 1 g, with the absolute maximum limit set at 1 g per day. The regimen frequently begins with a lower, introductory dose of 250 mg taken twice daily, which is then gradually increased, a process known as titration. The total daily dose is generally given in divided doses, though once-daily dosing may be permitted if tolerated. The medicine is often taken without food, but it can be taken after meals if stomach upset occurs.

Administration Requirements

A requirement for the use of this medication is the simultaneous use of Pyridoxine (Vitamin B6), often 100 mg or more per day, which is integrated into the treatment plan. For patients unable to swallow the capsule, the contents may be dispersed in drinking water to facilitate use. The overall duration of therapy for tuberculosis is long-term, extending over a period of 18 to 24 months. For patients with significant renal impairment, the dose requires reduction, with protocols specifying 250 mg once daily or thrice weekly. Therapeutic Drug Monitoring (TDM) is also used to guide the final dosage and ensure plasma levels remain below a defined threshold (e.g., 30–35 1mug/mL) for proper management.

Research evidence / Overview of studies for Циклосерин

Evidence for Multidrug-Resistant Tuberculosis (MDR-TB)

Cycloserine was studied for its use as a component in treatment regimens for Multidrug-Resistant Tuberculosis (MDR-TB). The research examined primarily systematic reviews and large observational cohort studies rather than randomized clinical trials. These studies monitored outcomes related to systemic or functional imbalance, specifically looking at how the infection evolves over the long period of treatment. The research examined changes in outcomes related to systemic or functional imbalance through milestones like microbiological clearance (often measured at 6 months) and the overall measured treatment outcome.

The findings describe patterns observed in the studies where the regimen component was studied for its association with observed treatment outcomes. Evidence is limited regarding the specific contribution of cycloserine alone due to a lack of large, comparative Randomized Controlled Trials (RCTs). Data for certain groups, such as those with Extensively Drug-Resistant Tuberculosis (XDR-TB), remain insufficient to draw strong conclusions.

Clinical Studies for Extrapulmonary Tuberculosis

For treating infections in difficult-to-reach areas, such as Tuberculous Meningitis (TBM), research examined whether the medicine can adequately reach the central nervous system. These studies explored outcomes by measuring drug concentration in the Cerebrospinal Fluid (CSF). This measurement was observed in studies as a surrogate marker used to inform regimen planning, not a direct measure of patient recovery. Certainty remains low because the studies primarily provide information about drug levels, and the link between these drug levels and the clinical outcome (such as patient survival or long-term neurological health) is not fully established.

Research in Specific Patient Groups (Special Populations)

Cycloserine was evaluated in studies that included different adult populations with MDR-TB, specifically including subgroups of patients who also have HIV co-infection or diabetes mellitus. Data for certain groups remain insufficient. For instance, evidence for use in children is limited and generally based on extrapolation from adult studies. Research describes significant inter-individual variability in drug concentration in the blood, meaning that the same dose may lead to different levels in different people, and research is ongoing regarding methods to monitor this variability.

Common questions about Циклосерин (FAQ)

Q: Is Cycloserine used only for tuberculosis, or are there other approved indications?

According to the official product information, Cycloserine is approved for the treatment of active forms of tuberculosis. Its use is specifically reserved for infections caused by strains of mycobacteria that are susceptible to the drug, particularly when primary, first-line treatments are determined to be ineffective.

Q: Can Cycloserine be used for other bacterial problems besides those in the instructions?

The main approved regulatory use for Cycloserine is strictly in the context of combination therapy for confirmed tuberculosis that shows resistance to other standard agents. Official documents outline the primary application of the medicine within these specific antitubercular needs.

Q: Does Cycloserine have other, lesser-known, approved indications?

The primary regulatory approved indications for Cycloserine are centered around the treatment of multidrug-resistant tuberculosis (MDR-TB) and related complex forms of the disease. Regulatory information primarily guides its use within these challenging treatment regimens.

Q: What are the most common side effects described in official sources for Cycloserine?

Official regulatory documents classify the frequency of most registered adverse reactions as "Unknown" or "Very rare" based on available data. Due to this classification, the specific side effects occurring most frequently cannot be reliably specified with a high frequency rating from the official prescribing information.

Q: How often, according to studies, do serious mood or behavior changes occur with Cycloserine?

Serious psychiatric issues, including psychoses or changes in mood and behavior, are noted in regulatory information as rare adverse reactions. These effects are associated with the drug's influence on the central nervous system (CNS).

Q: Are there interactions of Cycloserine with widespread vitamins or food supplements?

Regulatory documents contain a critical requirement for the mandatory simultaneous intake of Pyridoxine (Vitamin B6). This is done specifically to help mitigate the risk of neurotoxicity associated with Cycloserine. Information regarding interactions with other common vitamins or general supplements is not uniformly specified in the regulatory text.

Q: Must specific foods, tea, or coffee be avoided when taking Cycloserine?

Official administration guidance states that patients should avoid food with a high fat content. This is because a high-fat meal has been documented to negatively affect the absorption of Cycloserine in the body. Specific restrictions related to tea or coffee consumption are not typically stated in the regulatory documentation.

Q: Does taking Cycloserine affect indicators for diabetes?

The official prescribing information notes that patients who have diabetes must undergo special monitoring of blood glucose levels while taking the medication. This requirement ensures careful management of diabetic indicators throughout the course of treatment.

Q: Is there information in scientific data about the safety and consequences of long-term (more than 1 year) use of Cycloserine?

Treatment for tuberculosis with Cycloserine is inherently long-term, typically lasting between 18 and 24 months. Official guidelines require regular monitoring of the patient's blood, liver function, and drug levels throughout this entire extended period to manage safety.

Q: What is the significance of Cycloserine's mechanism of action in the context of drug resistance?

Cycloserine's mechanism works by differing from that of standard first-line antituberculosis agents. This unique mechanism allows the drug to be used against bacterial strains that have developed resistance to those standard treatments, positioning it as a tool for complex cases.

Q: Can Cycloserine cause sleep problems or insomnia?

Yes, official regulatory documents list insomnia as one of the potential side effects. This is classified as a reaction related to the drug's activity in the central nervous system (CNS).

Q: Are there special restrictions or requirements for elderly people taking Cycloserine?

Regulatory information indicates that clinical studies have not identified specific safety or effectiveness differences between elderly and younger adult patients, provided renal function is adequate.

Q: Is dose adjustment of Cycloserine required for people with liver diseases?

Regulatory information indicates that Cycloserine is primarily eliminated from the body by the kidneys. Consequently, a specific dose adjustment for patients with pre-existing liver diseases is usually not required.

Q: What general information is available about the protocol for action if a dose is missed?

General patient information indicates that if a dose is missed but noticed within a few hours, the dose is typically advised to be administered. If the delay is noticed closer to the time of the next scheduled dose, the missed dose is usually skipped.

Q: How do doctors determine that Cycloserine is a suitable choice for treating a specific patient?

The clinical decision to use this medicine is guided by the results of specific susceptibility tests. These tests confirm whether the patient's infection is multidrug-resistant ( MDR-TB) and whether the bacteria are susceptible to Cycloserine itself.

How to Store and Dispose of Cycloserine

Cycloserine capsules must be stored at Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling mandates specific protection to ensure stability:

• Temperature: Do not allow the medicine to freeze.
• Environment: Store the container tightly closed and away from heat, moisture, and direct light.

Packaging and Safety

Official labeling requires the medicine to be kept in a closed container and strictly out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Cycloserine via wastewater or household waste. The official procedure requires consulting a pharmacist to discard the medicine properly, ensuring the measures taken help protect the environment.